Cutia Therapeutics
HKSE: 2487.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lele Zhang
- Employees
- 333
- Headquarters
- Shanghai, China
- IPO year
- 2023
- Market cap
- HK$1.7B
- Website
- https://www.cutiatx.com
Loading 2487…
Loading profile data…Frequently asked questions about 2487
What does Cutia Therapeutics (2487.HK) do?
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The comp...
Where does 2487.HK trade?
Cutia Therapeutics (2487.HK) trades on the Hong Kong Stock Exchange.
What sector is 2487.HK in?
Cutia Therapeutics (2487.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cutia Therapeutics?
Lele Zhang is the chief executive officer of Cutia Therapeutics (2487.HK).
Where is Cutia Therapeutics headquartered?
Cutia Therapeutics is headquartered in China.
Does 2487.HK pay a dividend?
Cutia Therapeutics (2487.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2487.HK go public?
Cutia Therapeutics (2487.HK) completed its initial public offering in 2023.